

Additional file 4

Supplementary Table 2. Comparison of HRQOL scores among different treatment groups

Treatment group	Non- IFX treatment group (level 1-3)				IFX treatment group (level 4)			Paired groups	
	1 (N=15)	2 (N=21)	3 (N=27)	Total (N=63)	<4 times ^a (N=17)	≥ 4times ^a (N=24)	Total (N=41)	Non- IFX (N=32)	IFX
DAI									
Before ^b	6.47	8.38	7.65	7.61	6.35	7.06	6.77	7.77	7.92
After ^b	1.53	1.17	1.52	1.40	2.09	0.42	1.11	1.42	1.39
Variation ^b	-4.93	-7.21	-6.13	-6.21	-4.26	-6.65	-5.66	-6.34	-6.53
Pvalue ^c	0.577	0.194	0.655	0.528	0.081		<0.001	0.702	
MCIBDQ									
Bowel symptoms									
Before ^b	43.80	44.17	47.25	45.37	41.76	41.25	41.46	47.85	39.28
After ^b	56.16	60.70	57.69	58.32	56.27	63.71	60.63	58.64	59.93
Variation ^b	12.30	16.37	10.39	12.83	14.51	22.46	19.16	10.56	20.65
Pvalue ^c	0.114	0.469	0.019	0.029	0.060		<0.001	0.007	
Systemic symptoms									
Before ^b	19.60	19.05	18.81	19.08	15.12	18.17	16.90	19.72	15.53
After ^b	24.36	25.87	22.85	24.21	24.18	28.63	26.78	24.78	26.59
Variation ^b	4.50	6.82	4.15	5.15	9.06	10.46	9.88	5.06	11.06
Pvalue ^c	0.046	0.189	0.008	0.006	0.615		<0.001	0.007	
Emotional function									
Before ^b	50.00	52.10	53.50	52.18	43.66	48.50	46.49	56.34	44.38
After ^b	59.73	67.84	64.30	64.47	60.35	72.88	67.68	67.09	66.72
Variation ^b	9.51	15.74	10.73	12.18	16.69	24.38	21.19	10.74	22.34
Pvalue ^c	0.028	0.221	0.022	0.010	0.154		<0.001	0.015	
Social function									
Before ^b	21.77	20.76	22.03	21.54	17.42	19.70	18.79	22.98	17.40
After ^b	26.86	28.55	26.23	27.16	23.89	30.65	27.94	27.45	27.67
Variation ^b	5.23	7.79	4.29	5.71	6.47	10.95	9.16	4.47	10.27
Pvalue ^c	0.196	0.640	0.054	0.086	0.192		<0.001	0.024	
Total MCIBDQ									
Before ^b	135.17	136.08	141.58	138.17	119.81	127.61	124.49	146.89	117.51
After ^b	167.10	181.77	171.07	173.67	164.18	195.85	183.19	177.09	181.05
Variation ^b	31.55	45.24	29.56	35.25	44.37	68.24	58.69	29.55	63.54
Pvalue ^c	0.066	0.303	0.019	0.015	0.127		<0.001	0.004	
Total SF-36									
Before ^b	88.53	89.26	95.76	92.03	78.80	88.54	84.50	95.20	79.58

After ^b	104.21	110.32	101.45	104.95	103.25	120.39	113.80	105.21	113.14
Variation ^b	14.34	21.66	6.20	12.94	22.22	31.85	28.14	10.45	32.40
<i>P</i> value ^c	0.084	0.389	0.001	0.004	0.269		<0.001		0.002
Health transition									
Before ^b	4.07	3.76	3.93	3.90	3.94	4.00	3.98	3.97	4.06
After ^b	2.73	2.33	2.59	2.54	2.94	1.42	2.05	2.72	1.94
Variation ^b	-1.33	-1.43	-1.33	-1.37	-1.00	-2.58	-1.93	-1.25	-2.13
<i>P</i> value ^c	0.273	0.298	0.125	0.102	0.002		<0.001		0.075

a, according to the times of IFX infusion till the last interview, subjects in IFX group were divided into 2 subgroups: <4 times and ≥ 4 times;

b, the mean scores before treatment or after treatment were calculated on all available data excluding the dropped domain scores; all the variations were defined as (score of the interview after treatment minus score of the interview before treatment) without dropped domains both before and after treatment;

c. Independent *t*-test and paired *t*-test were applied. *P* values in the groups of treatment level 1, 2 or 3 were assessed by comparing the score variance between level 1 and level 4, level 2 and level 4, and level 3 and level 4, respectively; *P* values in the total non-IFX treatment group were assessed by comparing the score variance between the total non-IFX treatment group and the total IFX treatment group; *P* values in subgroups of IFX treatment group were assessed by comparing the score variance between these two subgroups; *P* values in total IFX treatment group were assessed by comparing the score variance between score of the 2nd interview and score of the 1st interview; *P* values in paired groups were assessed by comparing the score variance between these two paired groups.

The data of missing responses were excluded according to setting of PASW Statistics 18.0. The *P* values in bold were those with significance at the 0.05 level (2-tailed).